Halozyme Therapeutics | HALO - Interest Expense On Debt


Halozyme Therapeutics reported $5.59M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 95.64B 94.98B Jun/2026
Baxter International USD 78M 20M Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Cytokinetics USD 34.83M 1.5M Jun/2026
DBV Technologies USD 461K 323.71K Mar/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
MannKind USD 14.82M 2.38M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Pfizer USD 667M 4M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
United Therapeutics USD 2.9M 200K Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025